Completed
Afrezza® Dosing Optimization Study
NCT04849845
- Conditions
- Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +13 more
- Locations
-
- AMCR Institute Escondido, California, United States
- Diablo Clinical Research Walnut Creek, California, United States